RESUMO
Bruxism is a repetitive jaw-muscle activity characterised by clenching or grinding of the teeth and/or by bracing or thrusting of the mandible. It can occur during sleep, indicated as sleep bruxism, or during wakefulness, indicated as awake bruxism. Exogenous risk indicators of sleep bruxism and/or awake bruxism are, among others, medications and addictive substances, whereas also several medications seem to have the potential to attenuate sleep bruxism and/or awake bruxism. The objective of this study was to present a narrative literature on medications and addictive substances potentially inducing or aggravating sleep bruxism and/or awake bruxism and on medications potentially attenuating sleep bruxism and/or awake bruxism. Literature reviews reporting evidence or indications for sleep bruxism and/or awake bruxism as an adverse effect of several (classes of) medications as well as some addictive substances and literature reviews on medications potentially attenuating sleep bruxism and/or awake bruxism were used as starting point and guidelines to describe the topics mentioned. Additionally, two literature searches were established on PubMed. Three types of bruxism were distinguished: sleep bruxism, awake bruxism and non-specified bruxism. Generally, there are insufficient evidence-based data to draw definite conclusions concerning medications and addictive substances inducing or aggravating sleep bruxism and/or awake bruxism as well as concerning medications attenuating sleep bruxism and/or awake bruxism. There are insufficient evidence-based data to draw definite conclusions concerning medications and addictive substances inducing or aggravating sleep bruxism and/or awake bruxism as well as concerning medications attenuating sleep bruxism and/or awake bruxism.
Assuntos
Bruxismo , Bruxismo do Sono , Transtornos Relacionados ao Uso de Substâncias , Bruxismo/tratamento farmacológico , Humanos , Sono , Bruxismo do Sono/tratamento farmacológico , VigíliaRESUMO
PURPOSE: To estimate causation of adverse drug reaction (ADR) reports, causality methods were developed from a theoretical perspective. In daily practice, not all information is relevant or available, decreasing the applicability. We developed a new causality documentation tool (CausDoc) where an algorithm is combined with expert judgement. The aim of this study is to test the validity and reliability of CausDoc for ADR reports on drugs and vaccines. METHODS: CausDoc provides 9 structured relevant questions. If information is available, an answer will be chosen. If not, the question is excluded. Causality outcome is based on the sum score of all answers divided by the included questions: ≤30%: unlikely, 31% to 70%: possible, 71% to 90%: probable, and >90%: certain. Other relevant information is taken into account by expert judgement in the final step by adjusting the outcome to a limited extent. After testing face validity on 12 ADR reports, sensitivity and specificity were tested on 40 ADR reports, compared with the Naranjo algorithm and WHO AEFI criteria, using the expert panel's judgements as a standard. Inter-rater reliability was tested using weighted Cohen kappa coefficient. RESULTS: Average sensitivity and specificity with CausDoc were 47% and 83% for drugs (29% and 78% with Naranjo) and 72% and 89% for vaccines (65% and 87% with WHO AEFI criteria). Reliability between the 2 couples of assessors: κ 0.48 and 0.75. CONCLUSIONS: CausDoc shows a better performance and allows for a better documentation of ADRs in clinical practice. This approach is useful in assessing the causality of adverse drug reactions.
Assuntos
Sistemas de Notificação de Reações Adversas a Medicamentos/estatística & dados numéricos , Causalidade , Interpretação Estatística de Dados , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia , Farmacovigilância , Algoritmos , Humanos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Vacinas/efeitos adversosAssuntos
Antiasmáticos/efeitos adversos , Oftalmopatias/induzido quimicamente , Miastenia Gravis/induzido quimicamente , Omalizumab/efeitos adversos , Antiasmáticos/administração & dosagem , Oftalmopatias/fisiopatologia , Humanos , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/fisiopatologia , Omalizumab/administração & dosagemRESUMO
BACKGROUND: Increasing numbers of patients are being treated with TNF-alpha inhibitors. Two patients in our outpatient clinic developed Merkel cell carcinoma during treatment with TNF alpha inhibitors. Since this is a very rare malignancy, this is a remarkable observation. CASE DESCRIPTION: A 70-year-old male with rheumatoid arthritis had been treated with etanercept for two years when he discovered a nodule on his elbow that started growing rapidly. It was diagnosed as Merkel cell carcinoma. Despite treatment, the patient died 2 years later. CONCLUSION: Merkel cell carcinoma is an aggressive malignancy with a clinically benign aspect. Patients treated with TNF-alpha inhibitors possibly have an increased risk of developing this malignancy.